Tasquinimod - An Overview
Individuals with Hepatic Impairment: No information regarding dose adjustment is presented during the maker's labeling. Depending on the literature overview, no dose adjustment is probably going essential in hepatic impairment.[seventeen]Genentech requested a hearing, which was granted in June 2011. The FDA ruled to withdraw the breast most cancers